Distinguished in Peripheral T-Cell Lymphoma

Yuankai K. Shi

160 Pujian Road, 
Shanghai, CN 
Distinguished in Peripheral T-Cell Lymphoma
160 Pujian Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Yuankai Shi practices in Shanghai, China. Shi is rated as a Distinguished expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Bone Marrow Transplant, and Tissue Biopsy.

Their clinical research consists of co-authoring 499 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 13 articles in the study of Peripheral T-Cell Lymphoma.

Locations

160 Pujian Road, Shanghai, 200120, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: X-396 (Ensartinib), Crizotinib
Study Phase: Phase 3
A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma
A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drugs: YIV-906, Sorafenib
Study Phase: Phase 2
A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Effect of RC108-ADC For Injection in Subjects With c-Met Positive Advanced Malignant Solid Tumors
A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Effect of RC108-ADC For Injection in Subjects With c-Met Positive Advanced Malignant Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
Study of Keynatinib in Patients With Advanced Non-small Cell Lung Cancer With Brain Metastasis or Progression of Brain Metastasis After Treatment With EGFR Inhibitor(s)
Study of Keynatinib in Patients With Advanced Non-small Cell Lung Cancer With Brain Metastasis or Progression of Brain Metastasis After Treatment With EGFR Inhibitor(s)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drug: Keynatinib
Study Phase: Phase 2
A Randomized, Double-blind, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of BPI-7711 Capsule in Locally Advanced or Recurrent/Metastatic Treatment-naïve Non-small Cell Lung Cancer Patients With EGFR Mutation
A Randomized, Double-blind, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of BPI-7711 Capsule in Locally Advanced or Recurrent/Metastatic Treatment-naïve Non-small Cell Lung Cancer Patients With EGFR Mutation
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drugs: BPI-7711, Gefitinib
Study Phase: Phase 3
A Phase III,Double-Blind, Randomised Study to Assess the Efficacy and Safety of ASK120067 Versus Gefitinib as First-Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase III,Double-Blind, Randomised Study to Assess the Efficacy and Safety of ASK120067 Versus Gefitinib as First-Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drug: ASK120067
Study Phase: Phase 3
A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Stage IIIB/IIIC or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Stage IIIB/IIIC or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Unknown
Publish Date: August 08, 2023
Intervention Type: Drug
Study Drugs: HLX10, HLX04, Carboplatin, Pemetrexed
Study Phase: Phase 3
A Phase IIb, Open-label, Single-arm Study to Assess the Safety and Efficacy of BPI-7711 Capsule in Patients With Metastatic or Recurrent Non-small Cell Lung Cancer With EGFR Mutation and T790M Mutation Positive.
A Phase IIb, Open-label, Single-arm Study to Assess the Safety and Efficacy of BPI-7711 Capsule in Patients With Metastatic or Recurrent Non-small Cell Lung Cancer With EGFR Mutation and T790M Mutation Positive.
Enrollment Status: Completed
Publish Date: May 19, 2022
Intervention Type: Drug
Study Drug: BPI-7711
Study Phase: Phase 2
Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors: A Phase Ia Study, Open-label, Dose-escalation Study
Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors: A Phase Ia Study, Open-label, Dose-escalation Study
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Clinical Trial to Evaluate the Efficacy and Safety of CX1106 in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma After Failure of or Unfit for Platinum-containing Therapy
A Clinical Trial to Evaluate the Efficacy and Safety of CX1106 in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma After Failure of or Unfit for Platinum-containing Therapy
Enrollment Status: Withdrawn
Publish Date: September 03, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors
A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors
Enrollment Status: Unknown
Publish Date: October 22, 2019
Intervention Type: Biological
Study Drug: JS001
Study Phase: Phase 1
Efficacy and Safety of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma: a Single-arm, Open-label, Multi-site, Exploratory Phase Ib Study
Efficacy and Safety of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma: a Single-arm, Open-label, Multi-site, Exploratory Phase Ib Study
Enrollment Status: Terminated
Publish Date: July 24, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of BPI-15086 in Patients With Epidermal Growth Factor Receptor T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Progressed on Previous EGFR Tyrosine Kinase Inhibitor Therapy
A Phase 1 Study of BPI-15086 in Patients With Epidermal Growth Factor Receptor T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Progressed on Previous EGFR Tyrosine Kinase Inhibitor Therapy
Enrollment Status: Completed
Publish Date: July 18, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI
A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI
Enrollment Status: Withdrawn
Publish Date: February 04, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 13 Less Clinical Trials

499 Total Publications

Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
Journal: Hepatology (Baltimore, Md.)
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shi's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 9 Advanced Conditions
View All 59 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile